AJR Your Link to CME
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Conti, P. S.
Right arrow Articles by Halls, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Conti, P. S.
Right arrow Articles by Halls, J. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

American Journal of Roentgenology, Vol 162, 1279-1286, Copyright © 1994 by American Roentgen Ray Society


ARTICLES

Positron emission tomography: a financial and operational analysis

PS Conti, JS Keppler and JM Halls
Department of Radiology, University of Southern California, Los Angeles 90033.

Positron emission tomography (PET) is an emerging clinical imaging technique that is facing the challenges of expansion in a period of imminent health care contraction and reform. Although PET began showing utility in clinical medicine in the mid-1980s [1], its proliferation into mainstream medical practice has not matched that of other new imaging technologies such as MR imaging. Many factors have contributed to this, including the changing health care economy, the high cost of PET, the length of time it takes to develop a PET facility, and its inherent complexity. In part because of the proliferation of the use of other technologies and the general explosion of costs, insurance carriers are now holding diagnostic techniques, including PET, to stricter standards of efficacy. New techniques must show improvement in long-term outcome of patients, a difficult task for diagnostic tools. In addition to these issues, PET is an expensive technology that requires highly trained multidisciplinary personnel. Questions have also been raised about the most appropriate mechanism for regulation of PET isotope preparation, leading to speculation about future regulatory requirements. The current pioneers of PET must meet these challenges in order for it to become a routine imaging technique. Because of its clinical value, PET will probably survive despite the challenges. For many reasons, though, not every hospital should necessarily develop PET services. Conversely, many hospitals without this technology should consider acquiring PET. The purpose of this article is to identify the financial, operational, and clinical challenges facing PET centers today, describe potential organizational configurations that may enable PET to survive in an antitechnology environment, and delineate which institutions should consider this new technology.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Roentgenol.Home page
M. Berger, M. K. Gould, and P. G. Barnett
The Cost of Positron Emission Tomography in Six United States Veterans Affairs Hospitals and Two Academic Medical Centers
Am. J. Roentgenol., August 1, 2003; 181(2): 359 - 365.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
J. S. Keppler and P. S. Conti
A Cost Analysis of Positron Emission Tomography
Am. J. Roentgenol., July 1, 2001; 177(1): 31 - 40.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
V. Bousson, J.-L. Moretti, P. Weinmann, N. Safi, F. Tamgac, C. Groiselle, V. de Beco, Y. Hillali, D. Valeyre, and J.-L. Breau
Assessment of Malignancy in Pulmonary Lesions: FDG Dual-Head Coincidence Gamma Camera Imaging in Association with Serum Tumor Marker Measurement
J. Nucl. Med., November 1, 2000; 41(11): 1801 - 1807.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
K. Fukuchi, K. Hayashida, H. Moriwaki, K. Fukushima, N. Kume, T. Katafuchi, M. Sago, M. Takamiya, and Y. Ishida
Brain Fluorine-18 Fluorodeoxyglucose Imaging with Dual-Head Coincidence Gamma Camera:Comparison with Dedicated Ring-Detector PositronEmission Tomography
AJNR Am. J. Neuroradiol., January 1, 2000; 21(1): 99 - 104.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. T. Mastin, W. E. Drane, E. M. Harman, J. J. Fenton, and L. Quesenberry
FDG SPECT in Patients With Lung Masses
Chest, April 1, 1999; 115(4): 1012 - 1017.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Roentgen Ray Society.